<DOC>
	<DOCNO>NCT02375958</DOCNO>
	<brief_summary>A first-in-human sttudy use PCA062 patient p-CAD positive solid tumor .</brief_summary>
	<brief_title>PCA062 pCAD-positive Tumors .</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female ≥ 18 year age 2 . Documented pCAD express tumor cell exception HNSCC ESCC . An archived tumor sample collect within 36 month prior baseline available , new tumor biopsy sample must available molecular prescreening . 3 . Consent tumor biopsy screen 4 . Progressive disease effective therapy exist 5 . Measurable disease per RECIST v1.1 criterion 6 . ECOG Performance status ≤ 2 Exclusion criterion : 1 . CNS metastatic involvement 2 . Clinically significant cardiac , respiratory , gastrointestinal , renal , hepatic neurological condition . 3 . A history serious allergic reaction , opinion investigator pose increase risk serious infusion reaction . 4 . Monocular vision medium opacity condition precludes monitor retina fundus , history ophthalmology exam retina cornea abnormalities 5 . Previously treat antipCAD biologic therapy . 6 . Received anticancer therapy within follow time frame prior first dose study treatment : Conventional cytotoxic chemotherapy : ≤4 week Biologic therapy ( eg , antibody ) , ADCs : ≤4 week Noncytotoxic small molecule therapeutic : ≤5 T1/2 ≤2 week ( whichever longer ) Other investigational agent : ≤4 week Radiation therapy ( palliative setting allow . ) : ≤4 week Major surgery : ≤2 week 7 . Patient range laboratory value define : Hematological value : Absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L Hemoglobin ( Hgb ) &lt; 9 g/dL Platelets &lt; 100 x 109/L Hepatic renal function Total bilirubin &gt; 1.5 x upper limit normal ( ULN ) . For patient Gilbert 's syndrome , total bilirubin &gt; 2.5 x ULN . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &gt; 3 x ULN patient without tumor involvement liver &gt; 5 x ULN patient tumor involvement liver . Serum creatinine &gt; 1.5 x ULN and/or measure creatinine clearance &lt; 40 ml/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PCA062 , Triple Negative Breast Cancer , Head &amp; Neck Cancer , Esophageal Cancer , pCAD , pcadherin , solid-tumors</keyword>
</DOC>